If you’ve been following the GLP-1 conversation, you’ve probably heard that a generic version is finally available. That’s true, but the details matter a lot more than the headlines suggest. There’s only one generic GLP-1 that’s actually FDA-approved for weight loss right now, the most popular options like Wegovy and Ozempic still don’t have generic versions, and the prices aren’t always as low as you’d hope.
I’ve had so many people in my life ask me about this over the past year. Friends, clients at the salon, family members. The same questions keep coming up: “Can I get a cheaper version of Ozempic?” “Is the generic one the same thing?” “Will my insurance cover it?” This article is the honest, practical answer to all of those questions, with real prices and no sugarcoating.
What’s Actually Available Right Now
Let me be straightforward about this, because the terminology gets confusing fast. There are several GLP-1 medications on the market. Only one of them has a generic version approved for weight loss. Here’s where things stand as of April 2026:
Generic liraglutide (generic Saxenda) — the only generic GLP-1 for weight loss. Teva Pharmaceuticals launched this in August 2025 after receiving FDA approval. It’s the same active ingredient as brand-name Saxenda, at the same 3 mg dose, in the same type of injection pen. It’s a daily injection (not weekly like Wegovy). Hikma Pharmaceuticals also has FDA approvals for generic liraglutide. Additional generic manufacturers may enter after February 2026, which could further drive down prices.
Generic liraglutide (generic Victoza) — for type 2 diabetes only. Teva launched this in June 2024, and Hikma has been approved as well. This version is at a lower dose (up to 1.8 mg) and is only FDA-approved for blood sugar management in type 2 diabetes, not for weight loss. Some doctors prescribe it off-label for weight loss, but insurance almost never covers it for that purpose.
Semaglutide (Wegovy, Ozempic) — NO generic available. This is the one most people are asking about, and the answer is no. Semaglutide is still patent-protected. There is no generic Wegovy or generic Ozempic. The oral Wegovy pill (25 mg) launched in January 2026, but it’s a brand-name product, not a generic. Wegovy has also been approved for liver disease (MASH), which may affect insurance coverage options for some patients.
Tirzepatide (Zepbound, Mounjaro) — NO generic available. Also patent-protected. No generic versions exist.
Orforglipron (Foundayo) — brand new, no generic. This is Eli Lilly’s oral GLP-1 pill, FDA-approved on April 1, 2026. It’s the first GLP-1 pill you can take without food or water restrictions. It’s a brand-name product, not a generic, but it’s priced more accessibly than the injectables.
What Do They Actually Cost?
This is where it gets real. The prices vary significantly depending on which medication, whether you have insurance, and which pharmacy you use.
Generic liraglutide (for weight loss, generic Saxenda): The wholesale acquisition cost is approximately $1,165 per month. At retail pharmacies, prices range from about $370 to $1,300 per month depending on your pharmacy and any discount programs. This is cheaper than brand-name Saxenda ($1,300 to $1,800 per month), but it’s not the dramatic price drop many people expected from a “generic.”
Brand-name Wegovy (injectable semaglutide): List price is about $1,349 per month. However, through Novo Nordisk’s NovoCare program, self-pay patients can get injectable Wegovy at $350 per month. The oral Wegovy pill is available at $149 to $299 per month through NovoCare.
Foundayo (orforglipron pill): Self-pay patients can start at $149 per month for the lowest dose, scaling up to $299 per month for the maintenance dose. With commercial insurance, eligible patients may pay as little as $25 per month through a savings card.
Medicare pricing (new for 2026): In late 2025, Novo Nordisk and Eli Lilly entered agreements with the U.S. government to make GLP-1 medications available through Medicare Part D for $245 per month, with a $50 copay for beneficiaries. This is significant because Medicare previously did not cover anti-obesity medications at all. Foundayo is expected to be available through Medicare Part D at $50 per month starting July 1, 2026.
How Effective Are They Compared to Each Other?
I want to be completely transparent about this because it matters for your expectations. These medications are not all equally effective for weight loss.
Generic liraglutide produces an average weight loss of about 8% of body weight, based on clinical trials. In a head-to-head study (STEP 8), liraglutide resulted in 6.4% weight loss compared to semaglutide’s 15.8% over 68 weeks. That’s a meaningful difference.
Semaglutide (Wegovy) averages about 15 to 17% weight loss. Tirzepatide (Zepbound) averages 20 to 22.5%. Orforglipron (Foundayo) showed about 12.4% weight loss at the highest dose in trials.
So yes, generic liraglutide is less effective than the newer options. But it’s also the most affordable FDA-approved option, and 8% body weight loss is still clinically meaningful. For many people, the choice isn’t between liraglutide and Wegovy. It’s between liraglutide and nothing, because the cost of the alternatives puts them out of reach.Insurance and Coverage: The Honest Picture
This is the part nobody wants to hear, but you need to know it before you get your hopes up.
Private insurance coverage for GLP-1 medications varies dramatically by plan. Many commercial plans now cover Wegovy or Zepbound for weight loss, but not all do. Generic liraglutide coverage is inconsistent, and plans that cover it for diabetes may not cover it for weight loss. Always call your insurance company before filling a prescription.
Medicare Part D now covers anti-obesity medications under the new 2025-2026 agreement with Novo Nordisk and Eli Lilly. Monthly costs for beneficiaries are capped at $50 for covered medications. This is a major change, as obesity medications were previously excluded from Medicare entirely.
Medicaid coverage varies by state. Some states cover GLP-1 medications for diabetes with little to no copay, but weight-loss coverage is less common. Check with your state’s Medicaid office.
Without insurance, your options are: generic liraglutide ($370-$1,300/month), Wegovy through NovoCare ($350/month injectable or $149-$299/month oral), Foundayo ($149-$299/month self-pay), or manufacturer assistance programs. Teva and Novo Nordisk both offer patient assistance programs for income-eligible patients.
Use platforms like GoodRx or SingleCare to compare pharmacy prices. The same medication can cost hundreds of dollars more or less depending on where you fill it.
What to Ask Your Doctor
If you’re considering a GLP-1 medication, going into that conversation prepared makes a real difference. Here are the questions worth asking:
“Based on my health history, which GLP-1 is appropriate for me?” Your doctor needs to evaluate your full medical picture, not just your weight. Conditions like thyroid cancer history, pancreatitis, or kidney issues can affect which medications are safe for you.
“Is the generic liraglutide a realistic option for my goals?” If cost is a major factor and you’d benefit from an FDA-approved weight-loss medication, generic liraglutide might be the right starting point. If your doctor feels you need stronger results, they might recommend starting with a newer medication and exploring coverage options.
“What will my insurance actually cover?” Ask your doctor’s office to run a prior authorization check before you fill anything. Many offices can verify coverage before you commit.
“What should I expect for side effects and how do we manage them?” Nausea, digestive issues, and appetite changes are common across all GLP-1 medications. Starting at a low dose and increasing gradually reduces these side effects significantly. Knowing this upfront helps you stick with it.
“What happens if I stop taking it?” Weight regain after stopping GLP-1 medications is well-documented. This is a conversation worth having early, because these medications are designed for long-term use, not short courses.
A Note About Compounded Versions
You’ve probably seen ads for compounded semaglutide or tirzepatide at much lower prices through telehealth platforms. I want to be careful here: compounded medications are not FDA-approved generic versions. They’re made by compounding pharmacies and may differ in purity, dosing, and quality. The FDA has issued warnings about some compounded GLP-1 products.
That doesn’t mean all compounded options are unsafe, but it does mean you should only use compounded medications from a licensed pharmacy, prescribed by a real healthcare provider who’s monitoring your progress. This isn’t the place to cut corners. Your health is worth getting this right.
Frequently Asked Questions
Is there a generic version of Wegovy or Ozempic?
No. Semaglutide (the active ingredient in Wegovy and Ozempic) is still patent-protected. No generic version exists as of April 2026. The only generic GLP-1 currently available is liraglutide, which is a generic version of Saxenda (for weight loss) and Victoza (for diabetes).
How much does generic liraglutide cost without insurance?
Retail prices range from about $370 to $1,300 per month depending on your pharmacy, dose, and available discount programs. Using a coupon service like GoodRx or SingleCare can bring prices down to the lower end of that range. Teva also offers a patient assistance program for eligible patients.
Is the generic as effective as Wegovy?
Generic liraglutide produces less weight loss on average (about 8% of body weight) compared to semaglutide/Wegovy (about 15-17%). However, liraglutide is clinically proven and FDA-approved for weight management. For many people, especially those who can’t access or afford newer options, it provides meaningful, real results.
Does Medicare cover GLP-1 medications now?
Yes. Starting in 2026, Medicare Part D covers anti-obesity medications including Wegovy, Zepbound, and Mounjaro at $245 per month with a $50 beneficiary copay, under agreements between drug manufacturers and the federal government. Foundayo is expected to be covered at $50 per month starting July 1, 2026.
What is Foundayo and how is it different?
Foundayo (orforglipron) is Eli Lilly’s oral GLP-1 pill, FDA-approved April 1, 2026. Unlike oral Wegovy, it can be taken at any time of day without food or water restrictions. It’s not a generic. It’s a new brand-name medication, but it’s priced more affordably than most GLP-1 injectables ($149-$299/month self-pay). In clinical trials, it produced about 12.4% weight loss at the highest dose.
This article is for informational purposes only and is not medical advice. GLP-1 medications are prescription drugs with potential side effects and contraindications. Always consult your doctor or healthcare provider before starting any medication.
